Sareum Holdings PLC Pre-Close Trading Statement (5815O)
22 August 2017 - 4:00PM
UK Regulatory
TIDMSAR
RNS Number : 5815O
Sareum Holdings PLC
22 August 2017
(AIM: SAR) 22 August 2017
SAREUM HOLDINGS PLC
("Sareum" or "the Company")
Pre-Close Trading Statement
Sareum Holdings plc (AIM: SAR), the specialist cancer drug
discovery and development business, provides the following trading
update ahead of its full year results for the year ending 30 June
2017.
The Company is pleased to report that subject to audit, it now
expects that the profit for the year after tax and cash at bank,
for its results for the year ended 30 June 2017, to be ahead of
market expectations.
An update on progress with its cancer and autoimmune disease
research and development programmes will be given in mid-late
October 2017 when the Company expects to report its full year
results.
For further information, please contact:
Sareum Holdings plc
Tim Mitchell 01223 497 700
WH Ireland Limited (Nominated Adviser and
Co-Broker)
Chris Fielding / James Sinclair-Ford 020 7220 1666
Hybridan LLP (Co-Broker)
Claire Noyce 020 3764 2341
Citigate Dewe Rogerson (Media
enquiries)
Shabnam Bashir/ Mark Swallow/
David Dible 020 7282 9571
Notes for editors:
Sareum is a drug discovery and development company delivering
targeted small molecule therapeutics, focusing on cancer and
autoimmune disease, and licensing them to pharmaceutical and
biotechnology companies at the preclinical or early clinical trials
stage.
Sareum operates an outsourced research model, working with
international collaborators and a world-wide network of research
providers. Its most advanced programme (Chk1) commenced clinical
trials in May 2016 and was licensed to NASDAQ-listed Sierra
Oncology in September 2016.
SKIL(R) (Sareum Kinase Inhibitor Library) is Sareum's drug
discovery technology platform that has so far produced the
Company's Aurora+FLT3 and TYK2 kinase cancer and autoimmune disease
research programmes, which are in the IND-enabling preclinical and
lead optimisation stages respectively. SKIL(R) can also generate
drug research programmes against other kinase targets.
Sareum Holdings plc is listed on the AIM market of the London
Stock Exchange, trading under the symbol SAR. For further
information, please visit www.sareum.co.uk
- Ends -
This information is provided by RNS
The company news service from the London Stock Exchange
END
TSTBSGDIRUDBGRB
(END) Dow Jones Newswires
August 22, 2017 02:00 ET (06:00 GMT)
Sareum (LSE:SAR)
Historical Stock Chart
From Apr 2024 to May 2024
Sareum (LSE:SAR)
Historical Stock Chart
From May 2023 to May 2024